Published: 9 January 2019
Author(s): Marco Marietta, Federico Banchelli, Piercamillo Pavesi, Cesare Manotti, Roberto Quintavalla, Tiziana Sinigaglia, Giuliana Guazzaloca, Corrado Pattacini, Stefano Urbinati, Vincenzo Livio Malavasi, Giuseppe Boriani, Claudio Voci, Roberto D'Amico, Nicola Magrini
Oral anticoagulants directly inhibiting Factor IIa o Factor Xa (DOAC) have been marketed in Italy for the prevention of cardiac embolism in patients affected by non-valvular atrial fibrillation (NVAF) since 2013.
